The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH₃COO)Cl₂(NH₃)₂(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake

Figure 7

AR in A2780 cells treated for 1 h with 2 (10 μM) in the absence (control) or in the presence of tetraethylammonium chloride (TEA, pretreatment, 20 mg·mL⁻¹), or 1-methyl-4-phenylpyridin-1-ium (MPP⁺, cotreatment, 2 mM), or cimetidine (CMT, cotreatment, 1.5 mM). data are the mean ± SD of three independent replicates and were compared using one-way analysis of variance (ANOVA) with the Tukey post-hoc test. Statistical analysis (inhibitors vs. controls): no indication = not significant,  < 0.05,  < 0.001.